Compounders of off-brand Zepbound lose a product line.

The official FDA shortage is over, and compounders have 60-90 days to stop violating Eli Lilly’s patent protection. “The ruling also previews what will happen when semaglutide — the active ingredient in Novo Nordisk’s (NVO -17.43%) Ozempic and Wegovy — comes off the administration’s drug shortage list.” ~ learn more